From MoneyWeek · · 50s
Three top-class smaller biotech firms to invest in
Three smaller biotech firms show high growth potential with 2027 regulatory decisions.
In brief
Three smaller biotech firms show high growth potential with 2027 regulatory decisions. Three smaller biotech firms have high growth potential with 2027 regulatory decisions. Originally reported by MoneyWeek.
Biotech innovation surge
Biotechnology companies see record innovation despite FDA staff turnover and patent expiries.
Biotech Growth Trust strategy
The Trust invests in small and mid-sized biotech firms developing first-in-class medicines.
United Therapeutics expansion
United Therapeutics expands into fibrosis market with Tyvaso expected to launch in spring 2027.
Vaxcyte vaccine progress
Vaxcyte reported positive Phase III results for pneumococcal vaccine with 2027 pediatric data expected.
Palvella Therapeutics target
Palvella targets 2027 launch for rapamycin gel for rare microcystic lymphatic malformations.
2027 regulatory milestones
All three firms expect key regulatory decisions in spring 2027 for potential market leadership.
At a glance
Three smaller biotech firms have high growth potential with 2027 regulatory decisions.
